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Background
The association of isolated tumor cells and micrometastases in regional lymph nodes 
with the clinical outcome of breast cancer is unclear.
Methods
We identified all patients in the Netherlands who underwent a sentinel-node biopsy 
for breast cancer before 2006 and had breast cancer with favorable primary-tumor 
characteristics and isolated tumor cells or micrometastases in the regional lymph 
nodes. Patients with node-negative disease were randomly selected from the years 
2000 and 2001. The primary end point was disease-free survival.
Results
We identified 856 patients with node-negative disease who had not received sys-
temic adjuvant therapy (the node-negative, no-adjuvant-therapy cohort), 856 patients 
with isolated tumor cells or micrometastases who had not received systemic adjuvant 
therapy (the node-positive, no-adjuvant-therapy cohort), and 995 patients with iso-
lated tumor cells or micrometastases who had received such treatment (the node-
positive, adjuvant-therapy cohort). The median follow-up was 5.1 years. The adjusted 
hazard ratio for disease events among patients with isolated tumor cells who did 
not receive systemic therapy, as compared with women with node-negative disease, 
was 1.50 (95% confidence interval [CI], 1.15 to 1.94); among patients with micro-
metastases, the adjusted hazard ratio was 1.56 (95% CI, 1.15 to 2.13). Among pa-
tients with isolated tumor cells or micrometastases, the adjusted hazard ratio was 
0.57 (95% CI, 0.45 to 0.73) in the node-positive, adjuvant-therapy cohort, as compared 
with the node-positive, no-adjuvant-therapy cohort.
Conclusions
Isolated tumor cells or micrometastases in regional lymph nodes were associated 
with a reduced 5-year rate of disease-free survival among women with favorable 
early-stage breast cancer who did not receive adjuvant therapy. In patients with 
isolated tumor cells or micrometastases who received adjuvant therapy, disease-free 
survival was improved.
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The status of the axillary lymph nodes is the most important prognostic factor in breast cancer.1 These nodes can 
be sampled by axillary lymph-node dissection or 
sentinel-node biopsy with or without subsequent 
axillary lymph-node dissection (these additional 
lymph nodes are denoted as nonsentinel nodes). 
Detailed examination of the sentinel node by 
means of serial sectioning with optional immuno-
histochemical staining permits the detection of 
small metastases or isolated tumor cells.2-4 Iso-
lated tumor cells (staged as pN0[i+], with depos-
its ≤0.2 mm) and micrometastases (staged as 
pN1mi, with deposits >0.2 to ≤2.0 mm) have 
been separate categories in the American Joint 
Committee on Cancer (AJCC) Cancer Staging Manual 
since 2002.5 The cutoff value of 0.2 mm was cho-
sen arbitrarily.
Most studies of the association of minimal 
lymph-node involvement with prognosis have in-
cluded patients who received a diagnosis of breast 
cancer before the use of sentinel-node biopsy be-
came widespread. Moreover, isolated tumor cells 
were seldom distinguished from micrometasta-
ses, which made their prognostic relevance de-
batable.6-10
The Dutch guidelines regarding the treatment 
of breast cancer do not recommend systemic ad-
juvant therapy for low-risk breast cancer with 
isolated tumor cells in a regional lymph node. 
Moreover, because of insufficient evidence con-
cerning micrometastases and prognosis, the guide-
lines provide no advice with respect to systemic 
adjuvant therapy for low-risk breast cancer with 
nodal micrometastases.11 Consequently, some pa-
tients with breast cancer and micrometastases in 
the Netherlands receive systemic adjuvant ther-
apy, and others do not. The aim of the MIRROR 
(Micrometastases and Isolated Tumor Cells: Rele-
vant and Robust or Rubbish?) study was to evalu-
ate the relationship, if any, between isolated tumor 
cells or micrometastases in the regional lymph 
nodes and clinical outcome in patients who had 
undergone a sentinel-node procedure and who 
did or did not receive systemic adjuvant therapy.
Me thods
Patients
We identified women with invasive breast cancer 
who had undergone a sentinel-node biopsy before 
2006 from the Netherlands Cancer Registry. We 
included consecutive patients with favorable pri-
mary tumor characteristics (i.e., tumors of ≤1 cm 
in diameter, irrespective of grade, or tumors >1 
to ≤3 cm, grade 1 or 2) for whom systemic adju-
vant therapy was not indicated according to the 
Dutch guidelines, version 2002.12 Among these 
women, we selected only patients with a final 
nodal status of isolated tumor cells or microme-
tastases detected on microscopical examination 
of the sentinel and nonsentinel lymph nodes (in 
patients who subsequently underwent axillary 
lymph-node dissection). If both the sentinel node 
and the nonsentinel node contained metastases, 
the largest metastasis determined the final nodal 
status. According to the guidelines, axillary lymph-
node dissection was generally recommended if 
isolated tumor cells or micrometastases were de-
tected in the sentinel node.12 Table 1 lists the 
proportion of patients in each cohort who under-
went axillary lymph-node dissection.
In addition to these patients, we randomly 
selected a control group of 1000 patients who 
had breast cancer that was classified as low-risk, 
node-negative disease and who underwent breast 
surgery and a sentinel-node biopsy with or with-
out an axillary lymph-node dissection in the pe-
riod from 2000 through 2001. We excluded pa-
tients who received neoadjuvant chemotherapy, 
had bilateral breast cancer, had a history of can-
cer, or had node-negative disease and received 
systemic adjuvant therapy. All 113 Dutch hospi-
tals and 60 pathology laboratories participated in 
the study (see Table 1 of the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org). The review board of the Nether-
lands Cancer Registry approved this study. The 
ethics committee of Maastricht University Medi-
cal Center concluded that no informed consent 
was required for this retrospective, observational 
study.
Data Collection
Registration clerks of all eight comprehensive can-
cer centers in the Netherlands collected data on 
patient and tumor characteristics, breast surgery, 
the sentinel-node biopsy, axillary lymph-node dis-
section, radiotherapy, systemic adjuvant therapy, 
the recurrence of disease or the occurrence of 
another malignant condition, and death during 
follow-up.
Pathological Review
Three pathologists who specialized in breast can-
cer reviewed all available original slides of the 
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Table 1. Baseline Characteristics of the Patients.*
Characteristic
All Patients  
(N = 2707)
Node-Negative, 
No Adjuvant 
Therapy  
(N = 856)
Node-Positive, 
No Adjuvant 
Therapy  
(N = 856)
P  
Value†
Node-Positive, 
Adjuvant Therapy  
(N = 995)
P  
Value‡
Age at diagnosis — yr <0.001 0.76
Median 57 59 57 56
Range 30–93 30–89 32–93 31–88
Tumor size — no. (%)
≤1 cm 801 (29.6) 346 (40.4) 236 (27.6) <0.001 219 (22.0) <0.001
>1 to ≤2 cm 1523 (56.3) 448 (52.3) 516 (60.3) 559 (56.2)
>2 to ≤3 cm 383 (14.1) 62 (7.2) 104 (12.1) 217 (21.8)
Tumor grade — no. (%)
1 910 (33.6) 317 (37.0) 308 (36.0) 0.25 285 (28.6) 0.003
2 1618 (59.8) 474 (55.4) 499 (58.3) 645 (64.8)
3 135 (5.0) 49 (5.7) 36 (4.2) 50 (5.0)
Unknown 44 (1.6) 16 (1.9) 13 (1.5) 15 (1.5)
Tumor type — no. (%)
Ductal 2065 (76.3) 652 (76.2) 643 (75.1) 0.03 770 (77.4) 0.52
Lobular 293 (10.8) 76 (8.9) 106 (12.4) 111 (11.2)
Other 349 (12.9) 128 (15.0) 107 (12.5) 114 (11.5)
Expression of estrogen receptors, progesterone  
receptors, or both — no. (%)
Yes 2468 (91.2) 761 (88.9) 768 (89.7) 0.14 939 (94.4) 0.001
No 160 (5.9) 50 (5.8) 67 (7.8) 43 (4.3)
Unknown 79 (2.9) 45 (5.3) 21 (2.5) 13 (1.3)
Nodal status — no. (%)§
pN0 856 (31.6) 856 (100.0) — NA — NA
pN0(i+) 819 (30.3) — 513 (59.9) NA 306 (30.8) 0.001
pN1mi 1032 (38.1) — 343 (40.1) 689 (69.2)
Type of surgery — no. (%)
Breast-conserving surgery 1922 (71.0) 633 (73.9) 599 (70.0) 0.07 690 (69.3) 0.77
Mastectomy 785 (29.0) 223 (26.1) 257 (30.0) 305 (30.7)
No. of sentinel lymph nodes removed    <0.001  0.17
Mean 1.9 1.8 2.0 1.9
Range 1–14 1–9 1–14 1–9
Axillary lymph-node dissection — no. (%)
No 1370 (50.6) 736 (86.0) 389 (45.4) <0.001 245 (24.6) <0.001
Yes 1337 (49.4) 120 (14.0) 467 (54.6) 750 (75.4)
Axillary lymph-node dissection, axillary 
 irradiation, or both — no. (%)
No 1218 (45.0) 732 (85.5) 333 (38.9) <0.001 153 (15.4) <0.001
Yes 1489 (55.0) 124 (14.5) 523 (61.1) 842 (84.6)
Systemic adjuvant therapy — no. (%)
Hormonal therapy 627 (23.2) — — NA 627 (63.0) NA
Chemotherapy 60 (2.2) — — 60 (6.0)
Both 308 (11.4) — — 308 (31.0)
* NA denotes not applicable.
† P values are for the comparison of the node-negative, no-adjuvant-therapy cohort with the node-positive, no-adjuvant-therapy cohort.
‡ P values are for the comparison of the node-positive, no-adjuvant-therapy cohort with the node-positive, adjuvant-therapy cohort.
§ Nodal status is the final nodal status after sentinel-node biopsy, with or without axillary lymph-node dissection, and after central review.
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sentinel nodes and of positive nodes obtained 
from patients who underwent an axillary lymph-
node dissection. These included slides stained 
with hematoxylin and eosin, slides stained for 
immunohistochemical analysis, and frozen sec-
tions. Additional sections were not obtained, and 
new immunohistochemical staining was not per-
formed. The grade of the primary tumor was as-
sessed if it was not available from the original 
pathology report.
Almost all participating pathology laboratories 
used a protocol in which the sentinel node was 
serially sectioned at least every 150 μm and at a 
minimum of three levels, with the use of keratin 
immunohistochemical staining if the hematoxy-
lin and eosin staining was negative. In contrast, 
the nonsentinel nodes were macroscopically sec-
tioned every 2 to 5 mm, and one section per slice 
was stained with hematoxylin and eosin.13 Tu-
mor deposits were classified according to the 
sixth edition of the AJCC Cancer Staging Manual.5
Cohorts
We identified three cohorts: patients with node-
negative disease who did not receive systemic ad-
juvant therapy (the node-negative, no-adjuvant-
therapy cohort), patients with isolated tumor 
cells or micrometastases in the regional lymph 
nodes who did not receive systemic adjuvant 
therapy (the node-positive, no-adjuvant-therapy 
cohort), and patients with isolated tumor cells or 
micrometastases in the regional lymph nodes who 
received systemic adjuvant therapy (the node-pos-
itive, adjuvant-therapy cohort). Adjuvant therapy 
was defined as any type of hormonal therapy, 
chemotherapy, or both.
To determine whether an association exists 
between the presence or absence of isolated tu-
mor cells or micrometastases in the regional 
lymph nodes and outcome, we compared the out-
come for patients in the node-negative, no-adju-
vant-therapy cohort with the outcome for patients 
in the node-positive, no-adjuvant-therapy cohort. 
For this latter cohort, we performed separate 
assessments of patients with isolated tumor cells 
and patients with micrometastases. To determine 
the effect of systemic adjuvant therapy on the 
outcome in patients with isolated tumor cells or 
micrometastases, we compared the outcomes in 
the cohort of patients who did not receive adju-
vant therapy with the outcomes in the adjuvant-
therapy cohort.
End Points
The primary end point was the 5-year rate of 
disease-free survival. The period of disease-free 
survival was defined as the interval from the date 
of diagnosis to locoregional recurrence, distant 
metastases, contralateral invasive breast cancer 
or ductal carcinoma in situ, another malignant 
condition, or death from any cause, whichever 
occurred first. Recurrence was a composite end 
point defined as locoregional recurrence, distant 
metastases, or invasive cancer or ductal carcino-
ma in situ in the contralateral breast.
Statistical Analysis
The chi-square test for trend was used to assess 
baseline differences between ordinal variables, 
and Student’s t-test was used for continuous 
variables. The Kaplan–Meier method was used to 
estimate the 5-year rate of disease-free survival. 
For patients who remained alive and disease-
free, data were censored at the date of the last 
contact.
A Cox proportional-hazards model was used 
to compare the cohorts and to adjust for known 
prognostic clinical and pathological variables. 
In the primary analysis, we included age at diag-
nosis, tumor size, tumor grade, hormone-recep-
tor status, and form of axillary treatment (node 
dissection, irradiation, or both, or no axillary 
treatment). We did not include axillary lymph-
node dissection as an additional variable in the 
Cox proportional-hazards model when comparing 
the node-negative, no-adjuvant-therapy cohort 
with the node-positive, no-adjuvant-therapy co-
hort, since axillary lymph-node dissection is not 
recommended in patients with a negative senti-
nel node.14 To exclude axillary lymph-node dis-
section as a confounder, we performed a sec-
ondary analysis in which axillary lymph-node 
dissection was included, comparing the node-
negative, no-adjuvant-therapy cohort and the node-
positive, no-adjuvant-therapy cohort. We did not 
consider hormone-receptor status when compar-
ing the cohort of patients with isolated tumor 
cells or micrometastases that received adjuvant 
therapy with the cohort that did not receive 
such therapy, since hormone-receptor status 
partially determined whether a patient was in-
cluded in the node-positive, no-adjuvant-therapy 
cohort or the node-positive, adjuvant-therapy 
cohort.
All reported P values are two-sided, and con-
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fidence intervals are at the 95% level. All analy-
ses were performed with the use of SAS software, 
version 8.2.15
R esult s
Patients
We identified 3181 women with breast cancer 
from the Netherlands Cancer Registry. We exclud-
ed 146 patients (4.6%) because of incomplete or 
unavailable material for pathological review and 
26 patients (0.8%) because of missing baseline 
characteristics. After pathological review, 302 pa-
tients (9.5%) were ineligible because of macro-
metastases (in 185 patients), unfavorable primary 
tumor characteristics (in 68 patients), noninvasive 
breast cancer (in 7 patients), unmeasurable size 
of metastasis (in 2 patients), or receipt of sys-
temic adjuvant therapy despite favorable node-
negative disease (in 40 patients).
The final study involved 2707 women: 856 
women with node-negative disease who did not 
receive systemic adjuvant therapy (31.6%), 856 
women with isolated tumor cells or micrometas-
tases who did not receive adjuvant therapy (31.6%), 
and 995 women with isolated tumor cells or 
micrometastases who received adjuvant therapy 
(36.8%).
Table 1 shows the baseline characteristics of 
the three cohorts. In the node-positive, no-adju-
vant-therapy cohort as compared with the node-
negative cohort, the tumors were larger (P<0.001), 
more patients had lobular carcinoma (P = 0.03), 
and more patients had undergone axillary lymph-
node dissection (P<0.001). In the node-positive, 
adjuvant-therapy cohort as compared with the 
node-positive, no-adjuvant-therapy cohort, the tu-
mors were larger (P<0.001), the differentiation 
grade was poorer (P = 0.003), more patients had 
micrometastases in the regional nodes (P<0.001), 
and more patients had undergone axillary lymph-
node dissection (P<0.001). Other differences (e.g., 
age at diagnosis, number of sentinel nodes re-
moved, and hormone-receptor status) were small 
in absolute terms, though they were statistically 
significant (Table 1).
The median duration of follow-up was 5.1 
years (range, 0.04 to 9.3). Ninety-five patients 
(3.5%) were lost to follow-up within 0.04 to 5.6 
years after diagnosis. At the last follow-up, 2261 
patients (83.5%) were free of disease.
The components of the composite end point 
of recurrence (contralateral breast cancer, loco-
regional recurrence, and distant metastases) all 
showed the same trend as that reported for the 
overall end point of disease recurrence (see Table 2 
in the Supplementary Appendix). More detailed 
analyses of each of the components were not pos-
sible, however, because of the small number of 
events.
Node-Negative, No-Adjuvant-Therapy Cohort 
vs. Node-Positive, No-Adjuvant-Therapy Cohort
The unadjusted 5-year rate of disease-free survival 
in the node-positive, no-adjuvant-therapy cohort 
was significantly reduced as compared with that 
in the node-negative, no-adjuvant-therapy cohort 
(76.5% vs. 85.7%, P<0.001) (Fig. 1A). Patients 
with isolated tumor cells who did not receive ad-
juvant therapy had a significantly reduced 5-year 
rate of disease-free survival as compared with 
patients in the node-negative, no-adjuvant-ther-
apy cohort (77.2% vs. 85.7%, P<0.001) (Fig. 1B), 
and patients with micrometastases who did not 
receive adjuvant therapy had a significantly reduced 
5-year rate of disease-free survival as compared 
with patients in the node-negative, no-adjuvant-
therapy cohort (75.9% vs. 85.7%, P = 0.002) (Fig. 
1B). In the cohort of node-positive patients who 
did not receive adjuvant therapy, the 5-year rate 
of disease-free survival was similar among pa-
tients with isolated tumor cells and those with 
micrometastases (77.2% and 75.9%, respectively; 
P = 0.77).
After adjustment for age at diagnosis, tumor 
size, tumor grade, and hormone-receptor status, 
there was an increased risk of events in the node-
positive, no-adjuvant-therapy cohort as compared 
with the node-negative, no-adjuvant-therapy co-
hort (hazard ratio, 1.51; 95% confidence interval 
[CI], 1.20 to 1.90) (Table 2). The hazard ratio 
among women with isolated tumor cells who did 
not receive adjuvant therapy, as compared with 
the node-negative, no-adjuvant-therapy cohort, 
was 1.50 (95% CI, 1.15 to 1.94), and the hazard 
ratio among women with micrometastases, as 
compared with the node-negative women, was 
1.56 (95% CI, 1.15 to 2.13) (Table 2). Age at di-
agnosis, tumor size, tumor grade, and hormone-
receptor status were also associated with the risk 
of events (Table 2). When axillary lymph-node 
dissection was included in the model, the results 
were essentially the same (Table 3 in the Supple-
mentary Appendix).
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No Adjuvant Therapy vs. Adjuvant Therapy 
among Node-Positive Patients
The unadjusted 5-year rate of disease-free sur-
vival among women with isolated tumor cells or 
micrometastases who did not receive adjuvant 
therapy was significantly reduced as compared 
with the rate in the node-positive, adjuvant-ther-
apy cohort (76.5% vs. 86.2%, P<0.001) (Fig. 2A). 
Patients with isolated tumor cells who did not 
receive adjuvant therapy had a significantly re-
duced 5-year rate of disease-free survival as com-
pared with women who did receive adjuvant ther-
apy (77.2% vs. 83.0%, P = 0.04) (Fig. 2B). Among 
women with micrometastases, the 5-year rate of 
disease-free survival was significantly reduced in 
the no-adjuvant-therapy cohort as compared with 
the adjuvant-therapy cohort (75.9% vs. 87.9%, 
P<0.001) (Fig. 2C). Within the node-positive, ad-
juvant-therapy cohort, the 5-year rate of disease-
free survival did not differ significantly between 
patients with isolated tumor cells and those with 
micrometastases (83.0% and 87.9%, respectively; 
P = 0.09).
After adjustment for age at diagnosis, tumor 
size, tumor grade, and axillary treatment or no 
axillary treatment, there remained a reduced risk 
of events in the node-positive, adjuvant-therapy 
cohort as compared with the node-positive, no-
adjuvant-therapy cohort (hazard ratio, 0.57; 95% 
CI, 0.45 to 0.73) (Table 3). The hazard ratios were 
similar for patients with isolated tumor cells 
(0.66; 95% CI, 0.46 to 0.95) and those with micro-
metastases (0.50; 95% CI, 0.35 to 0.72) (Table 3). 
Also, age at diagnosis, tumor size, tumor grade, 
and axillary treatment or no axillary treatment 
were associated with the risk of events (Table 3).
In the node-positive, adjuvant-therapy cohort, 
the subgroup of patients who received chemo-
therapy only was small (60 patients), which 
limited statistical analysis according to treat-
ment, though patients who received combined 
chemotherapy and endocrine treatment seemed 
to have the largest benefit, as compared with 
patients in the node-positive, no-adjuvant-therapy 
cohort (adjusted hazard ratio, 0.34; 95% CI, 0.21 
to 0.55). The outcomes according to the type of 
adjuvant systemic therapy are shown in Tables 4 
and 5 in the Supplementary Appendix.
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Figure 1. Disease-free Survival among Patients with Early Breast Cancer 
with or without Isolated Tumor Cells or Microm tastases Who Did Not 
 Receive Systemic Adjuvant Therapy.
Panel A shows disease-free survival among patients with node-negative 
disease and among patients with isolated tumor cells or micrometastases. 
Panel B shows disease-free survival among patients with node-negative dis-
ease, patients with isolated tumor cells, and patients with micrometastases.
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Discussion
In this study, we determined whether a relation-
ship exists between disease-free survival and the 
presence of isolated tumor cells or micrometas-
tases as the final nodal status in women with 
favorable primary-tumor characteristics who un-
derwent a sentinel-node biopsy. All sentinel nodes 
and positive nonsentinel nodes were centrally re-
viewed, and separate analyses of the outcomes of 
patients who did or did not receive systemic adju-
vant therapy were performed. We found that micro-
metastases or isolated tumor cells in the regional 
lymph nodes were associated with an absolute 
reduction in the 5-year rate of disease-free survival 
of nearly 10 percentage points. Among patients 
who received systemic adjuvant therapy, the 5-year 
rate of disease-free survival was significantly im-
proved, with an absolute benefit of nearly 10 per-
centage points.
The presence of tumor-cell deposits in re-
gional lymph nodes may reflect the potential of 
the primary tumor to metastasize. The size of the 
tumor deposit may not be an influence on the 
outcome, since patients with isolated tumor cells 
or micrometastases had a comparably poor 5-year 
rate of disease-free survival. We did not differen-
tiate between single tumor cells (which may not 
have metastatic potential)16,17 and clusters of cells 
with an unknown potential for metastasis; this 
difference requires clarification. In current stag-
ing systems for breast cancer, lymph nodes con-
taining micrometastases are classified as node-
positive (pN1mi), whereas nodes containing 
isolated tumor cells are classified as node-nega-
tive (pN0[i+]).5,18 In view of our results, a re-
evaluation of the current AJCC classification is 
warranted.
Since the introduction of the sentinel-node bi-
opsy, there has been renewed interest in the prog-
nostic implications of the presence of isolated 
tumor cells and micrometastases. Most previous 
studies have shown reduced survival among 
women with occult metastases in lymph nodes, 
as compared with women with no nodal metas-
tases, although the difference was not always 
confirmed in multivariate analyses.6-8,19,20 Large 
studies that included women who received a di-
agnosis before the sentinel-node era showed that 
micrometastases, defined as 2 mm or smaller in 
diameter and including isolated tumor cells, were 
associated with reduced overall survival.9,10,21-24 In 
these studies, however, the axillary nodes were 
examined by means of hematoxylin and eosin 
staining at just one level. Thus, we cannot com-
pare these studies with ours, which involved a 
detailed examination of the sentinel node. The 
few previous studies of sentinel nodes were lim-
ited by small samples, lack of multivariate analy-
ses, or short follow-up.25-27
A drawback of our study is that most of our 
patients received a diagnosis when the Dutch 
guidelines for management of breast cancer were 
conservative, advising systemic adjuvant therapy 
in patients with node-negative disease only if the 
estimated 10-year probability of overall survival 
was less than 80%.12 Now, because of changes 
in the guidelines, more patients receive systemic 
therapy.11 Therefore, isolated tumor cells or mi-
crometastases should have a smaller influence 
on disease-free survival among patients with 
early-stage breast cancer. However, since chemo-
therapy now usually consists of potent third-
generation regimens, instead of the first- or 
second-generation regimens that were given in 
69% and 29%, respectively, of our patients who 
received chemotherapy, the impact of systemic 
therapy should be increased.
In this cohort study, the decision to adminis-
ter systemic adjuvant therapy was at the discretion 
of the physician. We corrected for factors that 
might have influenced this decision, such as age 
at diagnosis, tumor size, and tumor grade. To 
rule out axillary lymph-node dissection as a con-
founder, we performed an additional analysis of 
the node-negative, no-adjuvant-therapy cohort ver-
sus the node-positive, no-adjuvant-therapy cohort 
with this variable included in the model, with 
essentially the same outcome (Table 3 in the Sup-
plementary Appendix). No conclusion was pos-
sible regarding the effect of axillary lymph-node 
dissection on disease-free survival and the recur-
Figure 2 (facing page). Disease-free Survival among 
 Patients with Early Breast Cancer and Isolated Tumor 
Cells or Micrometastases Who Received Systemic 
 Adjuvant Therapy and Those Who Did Not.
Panel A shows disease-free survival among all patients 
with isolated tumor cells or micrometastases, Panel B 
shows disease-free survival among patients with isolated 
tumor cells, and Panel C shows disease-free survival 
among patients with micrometastases.
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rence rate in the axilla. To address that question, 
analyses have to be based on the sentinel-node 
status instead of the final nodal status.
Supported by a grant from the Netherlands Organization for 
Health Research and Development (945-06-509) and by the Dutch 
Breast Cancer Trialists’ Group.
Presented in part at the San Antonio Breast Cancer Sympo-
sium, San Antonio, Texas, December 10–14, 2008. 
No potential conflict of interest relevant to this article was 
reported.
We thank Jolanda M. van Beek-Schoester for her assistance 
with data management and Wim A.J.G. Lemmens for his assis-
tance with statistical analyses.
References
Fisher B, Bauer M, Wickerham DL, et 1. 
al. Relation of number of positive axillary 
nodes to the prognosis of patients with 
primary breast cancer: an NSABP update. 
Cancer 1983;52:1551-7.
van der Heiden-van der Loo M, Beze-2. 
mer PD, Hennipman A, et al. Introduction 
of sentinel node biopsy and stage migra-
tion of breast cancer. Eur J Surg Oncol 
2006;32:710-4.
Cserni G, Amendoeira I, Apostolikas 3. 
N, et al. Pathological work-up of sentinel 
lymph nodes in breast cancer: review of 
current data to be considered for the for-
mulation of guidelines. Eur J Cancer 2003; 
39:1654-67.
Bolster MJ, Bult P, Schapers RF, et al. 4. 
Differences in sentinel lymph node pathol-
ogy protocols lead to differences in surgi-
cal strategy in breast cancer patients. Ann 
Surg Oncol 2006;13:1466-73.
Green FL, Page DL, Fleming ID, et al. 5. 
eds. AJCC cancer staging manual. 6th ed. 
Chicago: American Joint Commission on 
Cancer, 2002.
Cote RJ, Peterson HF, Chaiwun B, et al. 6. 
Role of immunohistochemical detection of 
lymph-node metastases in management of 
breast cancer. Lancet 1999;354:896-900.
de Mascarel I, Bonichon F, Coindre 7. 
JM, Trojani M. Prognostic significance of 
breast cancer axillary lymph node micro-
metastases assessed by two special tech-
niques: reevaluation with longer follow-up. 
Br J Cancer 1992;66:523-7.
Tan LK, Giri D, Hummer AJ, et al. Oc-8. 
cult axillary node metastases in breast can-
cer are prognostically significant: results 
in 368 node-negative patients with 20-year 
follow-up. J Clin Oncol 2008;26:1803-9.
Chen SL, Hoehne FM, Giuliano AE. 9. 
The prognostic significance of microme-
tastases in breast cancer: a SEER popula-
tion-based analysis. Ann Surg Oncol 2007; 
14:3378-84.
Colleoni M, Rotmensz N, Peruzzotti G, 10. 
et al. Size of breast cancer metastases in 
axillary lymph nodes: clinical relevance of 
minimal lymph node involvement. J Clin 
Oncol 2005;23:1379-89.
Struikmans H, Nortier JW, Rutgers EJ, 11. 
et al. Guidelines ‘Treatment of breast can-
cer 2008’ (revision). Ned Tijdschr Geneeskd 
2008;152:2507-11. (In Dutch.)
Rutgers EJ, Nortier JW, Tuut MK, et al. 12. 
Dutch Institute for Healthcare Improve-
ment guidelines, “Treatment of breast 
cancer.” Ned Tijdschr Geneeskd 2002;146: 
2144-51. (In Dutch.) [Erratum, Ned Tijd-
schr Geneeskd 2003;147:2612.]
Treatment of breast cancer: guide-13. 
lines. Utrecht, the Netherlands: Dutch In-
stitute for Healthcare Improvement (CBO)
NABON, 2002. (In Dutch.)
Lyman GH, Giuliano AE, Somerfield 14. 
MR, et al. American Society of Clinical 
Oncology guideline recommendations for 
sentinel lymph node biopsy in early-stage 
breast cancer. J Clin Oncol 2005;23:7703-
20.
SAS/STAT user’s guide, version 8. Cary, 15. 
NC: SAS Institute, 1999.
Bleiweiss IJ, Nagi CS, Jaffer S. Axillary 16. 
sentinel lymph nodes can be falsely posi-
tive due to iatrogenic displacement and 
transport of benign epithelial cells in pa-
tients with breast carcinoma. J Clin Oncol 
2006;24:2013-8.
van Deurzen CH, Bult P, de Boer M, 17. 
et al. Morphometry of isolated tumor cells 
in breast cancer sentinel lymph nodes: 
metastases or displacement? Am J Surg 
Pathol 2009;33:106-10.
Sobin LH, Wittekind Ch. TNM classi-18. 
fication of malignant tumours. 6th ed. 
New York: Wiley-Liss, 2002.
Cummings MC, Walsh MD, Hohn BG, 19. 
Bennett IC, Wright RG, McGuckin MA. 
Occult axillary lymph node metastases in 
breast cancer do matter: results of 10-year 
survival analysis. Am J Surg Pathol 2002; 
26:1286-95.
Millis RR, Springall R, Lee AH, Ryder 20. 
K, Rytina ER, Fentiman IS. Occult axillary 
lymph node metastases are of no prog-
nostic significance in breast cancer. Br J 
Cancer 2002;86:396-401.
Grabau D, Jensen MB, Rank F, Blichert-21. 
Toft M. Axillary lymph node micrometas-
tases in invasive breast cancer: national 
figures on incidence and overall survival. 
APMIS 2007;115:828-37.
Kuijt GP, Voogd AC, van de Poll-Franse 22. 
LV, Scheijmans LJ, van Beek MW, Roumen 
RM. The prognostic significance of axil-
lary lymph-node micrometastases in breast 
cancer patients. Eur J Surg Oncol 2005; 
31:500-5.
Maibenco DC, Dombi GW, Kau TY, 23. 
Severson RK. Significance of micrometas-
tases on the survival of women with T1 
breast cancer. Cancer 2006;107:1234-9.
Truong PT, Vinh-Hung V, Cserni G, 24. 
Woodward WA, Tai P, Vlastos G. The num-
ber of positive nodes and the ratio of 
positive to excised nodes are significant 
predictors of survival in women with mi-
crometastatic node-positive breast cancer. 
Eur J Cancer 2008;44:1670-7.
Fan YG, Tan YY, Wu CT, et al. The ef-25. 
fect of sentinel node tumor burden on non-
sentinel node status and recurrence rates 
in breast cancer. Ann Surg Oncol 2005;12: 
705-11.
Cox CE, Kiluk JV, Riker AI, et al. Sig-26. 
nificance of sentinel lymph node micro-
metastases in human breast cancer. J Am 
Coll Surg 2008;206:261-8.
Gobardhan PD, Elias SG, Madsen EV, 27. 
et al. Prognostic value of micrometastases 
in sentinel lymph nodes of patients with 
breast carcinoma: a cohort study. Ann 
Oncol 2009;20:41-8.
Copyright © 2009 Massachusetts Medical Society.
powerpoint slides of journal figures and tables
At the Journal’s Web site, subscribers can automatically create PowerPoint slides.  
In a figure or table in the full-text version of any article at NEJM.org, click  
on Get PowerPoint Slide. A PowerPoint slide containing the image, with its title  
and reference citation, can then be downloaded and saved.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY LIBRARY UTRECHT on May 2, 2011. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
